U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07820098) titled 'Topical Delgocitinib for Facial Vitiligo' on Sept. 09.
Brief Summary: This study is looking at a skin condition called vitiligo. Vitiligo is a skin condition where patches of the skin lose their natural color and become white. This study focuses specifically on vitiligo that affects the face. The treatment being tested is a cream called Anzupgo, which contains an active ingredient named delgocitinib. This cream is applied directly to the skin in the areas affected by vitiligo.The purpose of this study is to find out whether delgocitinib cream could be a helpful treatment for people who have non-segmental vitiligo on their face. Dur...